Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,296 papers from all fields of science
Search
Sign In
Create Free Account
interferon beta-1b 0.3 MG Injection [Betaseron]
Known as:
INTERFERON BETA-1B 0.3MG/VIL (BETASERON)
, INTERFERON BETA-1B,RECOMBINANT 0.3MG/VIL (BETASERON)
, Betaseron 0.3 MG Injection
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
10 relations
Albumin Human, USP
Betaseron
Drug Allergy
Injection
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Ein Paradigmenwechsel und die Zukunft
O. Aktaş
2013
Corpus ID: 162780270
In der wechselvollen und sehr dynamischen Entwicklung der Therapien der Multiplen Sklerose (MS) stellt Interferon beta-1b…
Expand
2012
2012
Spotlight on Interferon-β-1b in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis
P. L. McCormack
,
L. Scott
BioDrugs
2012
Corpus ID: 30256113
Interferon-β-1b (Betaseron®, Betaferon®) is a non-glycosylated recombinant human interferon-β approved for high-frequency…
Expand
Review
2009
Review
2009
Dose response to interferon therapy in multiple sclerosis: an evaluation of the evidence
S. Freedman
2009
Corpus ID: 73287679
ABSTRACT Background: Interferon beta (IFNβ) is a disease-modifying therapy for multiple sclerosis (MS). Although clinical…
Expand
2009
2009
Effect of anti-IFNβ antibodies on MRI lesions of MS patients in the BECOME study
A. Pachner
,
D. Cadavid
,
L. Wolansky
,
J. Skurnick
Neurology
2009
Corpus ID: 41226195
Background: Interferon beta (IFNβ) administered subcutaneously is immunogenic in some patients with multiple sclerosis (MS) and…
Expand
2008
2008
The Use of Disease-Modifying Agents in Multiple Sclerosis - by the Canadian Network of MS Clinics
P. O'Connor
Canadian Journal of Neurological Sciences…
2008
Corpus ID: 23698338
Health Canada approved medications for the treatment of multiple sclerosis (MS): Avonex® (Interferon Beta 1a), Betaseron…
Expand
2004
2004
The safety, tolerability and pharmacodynamic responses of interferon BETA‐1A (Rebif®) versus interferon BETA‐1B (Betaseron®) in healthy male volunteers
S. Gariepy
,
J. Marier
,
D. Potvin
,
M. D. Di Marco
,
W. Byrnes
,
A. Abdul-Ahad
2004
Corpus ID: 73324716
1998
1998
Recent advances in preclinical drug development in multiple sclerosis
C. Hoban
1998
Corpus ID: 72369759
Recently approved therapies for treatment of relapsing-remitting multiple sclerosis (MS) include interferon β1b (IFNβ1b…
Expand
1998
1998
Neutralizing Antibodies to Interferon β-1a (IFNβ-1a; Avonex™) and Interferon β-1b (IFN β-1b; Betaseron®) are Cross Reactive
Omar Khan
,
S. Dhib-Jalbut
Neurology
1998
Corpus ID: 72260529
“Late Breaking News” (formerly “Works in Progress”) is a feature of the Scientific Program of the American Academy of Neurology…
Expand
1993
1993
Beyond Betaseron®: current directions for MS research
S. Henahan
1993
Corpus ID: 71600838
The approval of Betaseron® has drawn attention to the potential of immune modulation as a means of treating multiple sclerosis…
Expand
1986
1986
The isolation of human beta-interferon receptor by wheat germ lectin affinity and immunosorbent column chromatographies.
Z. Zhang
,
A. Fournier
,
Y. H. Tan
Journal of Biological Chemistry
1986
Corpus ID: 9284257
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE